Newsroom

Sorted by: Latest
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust FactorFX UCITS ETF 06.07.2026 FXGB LN IE00BD5HBR05 47,692.00 GBP 976,164.75 27.338  ...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust IPOX Europe Equity Opportunities UCITS ETF 06.07.2026 IPXE.IM IE00BFD26097 50,002.00 EUR 1,321,297.47 26.425  ...
-

BrainCheck Selected for Three Poster Presentations at the 2026 Alzheimer’s Association International Conference

AUSTIN, Texas & NEW YORK--(BUSINESS WIRE)--BrainCheck Inc., a cognitive workflow platform, today announced that three of its research submissions have been accepted for poster presentations at the 2026 Alzheimer’s Association International Conference (AAIC), taking place July 12-15 in London, United Kingdom. The accepted abstracts span clinical validation, care planning outcomes, and international adaptation of the BrainCheck platform. AAIC is the world’s largest forum for the dementia research...
-

Pet Honesty®, Fastest Growing Cat Supplement Brand in the U.S., Launches Cat Squeezables™, Bringing Science-Backed Wellness to a Format Cats Already Love

AUSTIN, Texas--(BUSINESS WIRE)--Pet Honesty launches Cat Squeezables, a new line of eight lickable purées that delivers targeted health benefits in a format cats naturally love....
-

Cyllene Therapeutics Raises €33 Million Series C

PARIS & BEVERLY HILLS, Calif.--(BUSINESS WIRE)--Cyllene Therapeutics (“Cyllene”), formerly known as EG 427, today announced the closing of a €33 million Series C financing round co-led by GordonMD Global Investments® LP (“GordonMD”) and Merck Ventures B.V., an affiliate of Merck KGaA, Darmstadt, Germany, as well as T. Andera Partners SAS, Bpifrance Investissement through its InnoBio 3 Fund, L.P., and Lamond Ventures LLC also participated in the round. Proceeds will advance the clinical developm...
-

CACI Continues Providing Forensic Analysis and Exploitation to U.S. Army DEVCOM C5ISR Center

RESTON, Va.--(BUSINESS WIRE)--CACI International Inc (NYSE: CACI) announced today that it has received a ceiling increase valued at more than $140.5 million for the remaining three years of its existing five-year contract to continue providing comprehensive forensic exploitation support to the U.S. Army Development Command (DEVCOM) Command, Control, Communications, Computers, Cyber, Intelligence, Surveillance and Reconnaissance (C5ISR) Center. With this increase, the total contract value will be...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Europe Growth Strength UCITS ETF 06.07.2026 FTEG.LN IE0009F7UB30 125,002.00 EUR 2,708,874.95 21.671  ...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Low Duration Global Government Bond UCITS ETF 06.07.2026 FGOV LN IE00BKS2X200 83,638.00 GBP 1,237,565.86 17.310  ...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest U.S. Equity Max Buffer UCITS ETF - September 06.07.2026 MSEP.LN IE0009DRFET8 50,002.00 USD 1,396,912.63 27.937  ...
-

Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis

WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics, Inc. (NASDAQ: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, today announced the completion of a comprehensive interim analysis of its ongoing adaptive Phase 2 clinical trial evaluating GX-03 for the treatment of atopic dermatitis. The multi-week review resulted in the final Stage 2 study design, incorporating data-driven refinements to patient selection, dise...